Healius Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Healius is gedaald met een gemiddeld jaarlijks percentage van -65.4%, terwijl de winst van de Healthcare -industrie jaarlijks daalde met 3.3%. De inkomsten zijn groeide met een gemiddeld percentage van 3.1% per jaar.

Belangrijke informatie

-65.4%

Groei van de winst

-64.9%

Groei van de winst per aandeel

Healthcare Groei van de industrie	2.4%
Inkomstengroei	3.1%
Rendement op eigen vermogen	-61.1%
Nettomarge	-36.4%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Healius geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

ASX:HLS Opbrengsten, kosten en inkomsten (AUD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Jun 24	1,746	-636	81
31 Dec 23	1,692	-984	79
30 Sep 23	1,699	-682	79
30 Jun 23	1,707	-380	76
31 Dec 22	1,839	35	90
30 Sep 22	2,064	164	100
30 Jun 22	2,289	292	110
31 Dec 21	2,292	226	106
30 Sep 21	2,103	146	96
30 Jun 21	1,914	66	86
31 Mar 21	1,802	75	90
31 Dec 20	1,690	83	93
30 Sep 20	1,630	83	87
30 Jun 20	1,570	83	82
31 Dec 19	1,502	110	227
30 Sep 19	1,534	83	226
30 Jun 19	1,566	57	225
31 Mar 19	1,785	29	269
31 Dec 18	1,752	2	259
30 Sep 18	1,728	3	251
30 Jun 18	1,705	4	244
31 Mar 18	1,694	-256	241
31 Dec 17	1,683	-516	238
30 Sep 17	1,671	-516	238
30 Jun 17	1,659	-517	238
31 Mar 17	1,648	-260	223
31 Dec 16	1,637	-3	209
30 Sep 16	1,639	18	209
30 Jun 16	1,642	38	209
31 Dec 15	1,595	126	183
30 Sep 15	1,587	121	183
30 Jun 15	1,580	117	183
31 Mar 15	1,596	127	185
31 Dec 14	1,572	118	178
30 Sep 14	1,548	116	178
30 Jun 14	1,524	115	178
31 Mar 14	1,501	134	144
31 Dec 13	1,478	131	140

Kwaliteitswinsten: HLS is momenteel verliesgevend.

Groeiende winstmarge: HLS is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: HLS is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 65.4% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van HLS over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: HLS is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Healthcare industrie ( -25.4% ).

Rendement op eigen vermogen

Hoge ROE: HLS heeft een negatief Return on Equity ( -61.11% ), omdat het momenteel verliesgevend is.

Healius Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2024 earnings: Revenues exceed analyst expectations

Healius Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Full year 2023 earnings: Revenues miss analyst expectations

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Recent updates

Price target increased by 14% to AU$1.77

Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million.

Price target increased by 8.4% to AU$1.68

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Healius Limited, Annual General Meeting, Nov 15, 2024

Price target increased by 7.5% to AU$1.51

Full year 2024 earnings: Revenues exceed analyst expectations

TPG Capital, PEP Reportedly Still Competing for Healius Lumus Imaging

Final Bids Reportedly Expected for Healius

Healius Limited Announces Step Down of Ravi Jeyaraj as Non-Executive Director, Effective 2 August 2024

Macquarie Unit Reportedly in Healius Race

Healius Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Sonic in the Running for Healius Imaging Business

Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit

High number of new directors

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Australian Clinical Labs Limited (ASX:ACL) cancelled the acquisition of Healius Limited (ASX:HLS) from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.

New minor risk - Shareholder dilution

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited, Annual General Meeting, Nov 01, 2023

Australian Clinical Labs Limited (ASX:ACL) canceled the acquisition of Healius Limited (ASX:HLS)

Healius Limited Appoints Michael Stanford as Director

Full year 2023 earnings: Revenues miss analyst expectations

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 37%

Consensus EPS estimates fall by 37%

Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023

Consensus EPS estimates increase by 34%

Consensus EPS estimates increase by 36%

Consensus EPS estimates increase by 22%

High number of new directors

Consensus EPS estimates increase by 18%

Is Healius Limited (ASX:HLS) Trading At A 50% Discount?

Independent Non Executive Chairman recently bought AU$103k worth of stock

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Consensus EPS estimates increase by 17%

Healius Limited Announces Resignation of Alison Stephenson as Company Secretary

Consensus EPS estimates fall by 21%

At AU$3.07, Is It Time To Put Healius Limited (ASX:HLS) On Your Watch List?

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Consensus forecasts updated

Price target decreased to AU$3.23

Consensus EPS estimates fall by 13%

Nexus Hospitals entered into an agreement to acquire Montserrat Healthcare Pty Ltd from Healius Limited (ASX:HLS).

Here's Why Healius (ASX:HLS) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 27%

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

MD, CEO & Director recently sold AU$660k worth of stock

Is Now An Opportune Moment To Examine Healius Limited (ASX:HLS)?

Brookfield Reportedly Drops Out of Race to Buy Healius

Independent Non Executive Director recently bought AU$86k worth of stock

Non Executive & Independent Director recently bought AU$70k worth of stock

MD, CEO & Director exercised options to buy AU$2.2m worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Healius Limited Announces Fully Franked Ordinary Paid Dividend for the Six Months Ended June 30, 2022, Payable on September 21, 2022

Healius Limited, Annual General Meeting, Oct 20, 2022

Are Investors Undervaluing Healius Limited (ASX:HLS) By 48%?

Healius Reportedly Launches Day Surgery Sale Process

Price target decreased to AU$4.30

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Consensus EPS estimates fall by 13%

Healius Limited to Report Fiscal Year 2022 Results on Aug 31, 2022

Why Healius Limited (ASX:HLS) Could Be Worth Watching